# DNTOX

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/dntox

- Industry: Biotechnology
- Headquarters: Düsseldorf, Germany
- Website: www.dntox.de
- Total disclosed funding: $1.5M
- Latest round: Seed (Feb 28, 2023)
- Investors on record: 3

## About

Based in Düsseldorf, Germany, and founded in 2022, DNTOX GmbH operates as a life science firm that offers animal-free in vitro test systems. The company is a spin-off of the IUF—Leibniz Institute for Environmental Medicine Research. In February 2023, DNTOX GmbH raised EUR 1.4 million in seed funding led by High-Tech Gründerfonds, Bool Capital, and AQAL Capital. The seed funding values DNTOX GmbH at EUR 7.40 million post-money.

The products and services offered by DNTOX include developmental neurotoxicity (DNT) testing, a bioanalytical testing platform that uses human cells like human pluripotent stem cells (hPSCs) and multicellular and multiplexed human-based 2D/3D in vitro systems to evaluate chemicals in the body; acute neurotoxicity testing, a test system that uses 3D hiPSC-derived BrainSpheres to identify neurotransmitter receptor subtypes; computational biology and bioinformatics, a software that develops machine learning-based microscopy image and video analysis; and model development.

The company plans to use the funds raised in February 2023 to construct its cell culture laboratories in Düsseldorf.

## Funding rounds

- Seed, Feb 28, 2023, $1.5M — High-Tech Gruenderfonds, AQAL Capital, Bool Capital

## Investors

- High-Tech Gruenderfonds (https://capitalatlas.ai/funds/high-tech-gruenderfonds) — Seed
- AQAL Capital (https://capitalatlas.ai/funds/aqal-capital) — Seed
- Bool Capital (https://capitalatlas.ai/funds/bool-capital) — Seed